Sanofi CEO Paul Hudson says, "AI is a huge opportunity, and we can't be deniers." ...

The candidates merge two existing vaccines that have demonstrated favourable tolerability through randomised controlled ...

The US Food and Drug Administration(FDA) has granted Fast Track designation to two non-mRNA combination vaccine candidates ...

Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...

A drug developed by Sanofi raised platelet counts and reduced bleeding episodes in patients with a rare autoimmune disorder ...

I think we were contrarians,” Sanofi’s chief digital officer, Emmanuel Frenehard, told Fortune. “I think the contrarians are ...

Sanofi (SNY) says new data from three oral presentations demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly ...

US FDA grants fast track designation to two Sanofi’s combination vaccine candidates to prevent influenza & Covid-19 infections: Paris Thursday, December 12, 2024, 10:00 Hrs [IST ...

Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...

Paris: The US Food and Drug Administration (USFDA) has granted Fast Track designation to two Sanofi combination vaccine ...

SHANGHAI, Dec 2 (Reuters) - Sanofi plans to invest around 1 billion euros ($1.05 billion) to build a new insulin production ...

Sanofi SA will invest around 1 billion euros ($1.1 billion) to build a new insulin production base in Beijing, its biggest ...